In addition, fetuin-A has been shown to promote cytokine expression and low-grade inflammation by activating several pathways potentially involved in the development of NAFLD/MASLD, insulin resistance, beta cell apoptosis, and T2D. Here, AHSG is linked to metabolic dysfunction-associated steatotic liver disease.